Elanco Animal Health (ELAN) Earnings Dates, Call Summary & Reports

475 Followers

Earnings Data

Report Date

Aug 10, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

0.27

Last Year’s EPS

0.26

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 12 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:May 06, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a materially positive picture: strong Q1 performance (10% organic growth, $1.371B revenue), major share gains and product momentum (Zenrelia, Credelio Quattro and Adtab), raised full-year guidance, meaningful EBITDA and EPS improvement, and a credible path to deleveraging supported by Elanco Ascend productivity plans and disciplined M&A. Near-term headwinds include a 40-basis-point gross margin decline in Q1, higher operating investments, regulatory work required for Zenrelia's U.S. label expansion, capacity scaling needs, and external timing effects (China/Middle East) and competitive risks that could temper near-term upside. Overall, the positives (outperformance, raised guidance, blockbuster product traction and clear balance-sheet focus) outweigh the manageable operational and timing risks discussed.

Company Guidance

Elanco raised its 2026 outlook, now targeting full-year organic constant‑currency revenue growth of 5–7% (reported revenue $5.01–$5.085B, including an expected ~$60M FX tailwind), increased its innovation revenue target to $1.2B (Q1 innovation revenue was $287M), and raised adjusted EBITDA guidance to $975M–$1.005B (≈10% at the midpoint; a $20M raise driven by $34M Q1 outperformance offset by ~$9M incremental launch spend); adjusted EPS guidance is $1.03–$1.09 (up $0.03, ~13% growth at the midpoint). Q1 results included $1.371B revenue (10% organic constant‑currency growth), $334M adjusted EBITDA and $0.40 adjusted EPS. Q2 guidance is $1.30–$1.325B revenue (organic CC +4–6%), $240M–$260M adjusted EBITDA and $0.25–$0.28 adjusted EPS. On the balance sheet, Q1 net debt was $3.3B (net leverage 3.5x); management tightened year‑end net leverage guidance to 3.0–3.2x (from 3.1–3.3x) with a path to <3x in 2027 and a long‑term target of 2.0–2.5x, and reiterated a goal of delivering >$1B free cash flow through 2028.

Strong Top-Line Growth

Reported revenue of $1.371 billion in Q1 2026, up 15% year-over-year; organic constant-currency revenue growth of 10% (driven by 2% price and 8% volume).

Robust Innovation Performance

Innovation revenue of $287 million in Q1; raised full-year innovation target by $50 million to $1.2 billion. 'Big 6' innovations driving broad-based growth and portfolio benefits.

Raised Full-Year Guidance

Full-year organic constant-currency revenue guidance raised to 5%–7% (from 4%–6%); adjusted EBITDA guidance increased to $975M–$1.005B (raised by $20M); adjusted EPS guidance increased to $1.03–$1.09 (raised by $0.03).

Margin-Adjusted Profitability Improvement

Q1 adjusted EBITDA of $334 million, up $58 million or 21% year-over-year; adjusted EPS of $0.40, up 8% year-over-year (note: prior-year tax benefit lapped).

Market Share Gains for Key New Products (Zenrelia & Credelio Quattro)

Zenrelia reached blockbuster status on a trailing 4-quarter basis, in >16,000 U.S. clinics (>50% U.S. penetration), >80% reorder rate and >2 million dogs treated; international Zenrelia share: Brazil >50% JAK share, Japan >35%, key EU markets high teens to >30%. Credelio Quattro: penetration in >40% of U.S. clinics, share within carrying clinics rose 13 points to 53%; added 2,500 new clinics year-to-date.

Broad-Based Quadrant Growth

U.S. Pet Health +6% (Q1), International Pet Health +9% organic cc, U.S. Farm Animal +15% organic cc, International Farm Animal +13% organic cc; OTC Adtab sales grew >50% in Europe.

Balance Sheet & Cash-Flow Progress

Net debt $3.3 billion and net leverage 3.5x in Q1; updated year-end net leverage target improved to 3.0–3.2x (from 3.1–3.3x) with a path to <3x in 2027; debt paydown remains primary use of free cash flow and management targets >$1 billion in free cash flow through 2028.

Operational Productivity Initiatives (Elanco Ascend)

Elanco Ascend logged >5,000 projects to date, with expected material savings (75% of benefits in gross margin over time, near-term benefits in G&A) and integration of automation/AI to drive efficiency and margin expansion.

Strategic M&A Execution

Completed AHV International acquisition (April 30), enhancing dairy/farm animal platform and expanding farm-animal capabilities.

Elanco Animal Health (ELAN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ELAN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 10, 2026	2026 (Q2)	0.27 / -	0.26	―	―	―
May 06, 2026	2026 (Q1)	0.35 / 0.40	0.37	8.11% (+0.03)
Feb 24, 2026	2025 (Q4)	0.11 / 0.13	0.14	-7.14% (-0.01)
Nov 05, 2025	2025 (Q3)	0.13 / 0.19	0.13	46.15% (+0.06)
Aug 07, 2025	2025 (Q2)	0.20 / 0.26	0.3	-13.33% (-0.04)
May 07, 2025	2025 (Q1)	0.31 / 0.37	0.34	8.82% (+0.03)
Feb 25, 2025	2024 (Q4)	0.15 / 0.14	0.08	75.00% (+0.06)
Nov 07, 2024	2024 (Q3)	0.12 / 0.13	0.18	-27.78% (-0.05)
Aug 08, 2024	2024 (Q2)	0.24 / 0.30	0.18	66.67% (+0.12)
May 08, 2024	2024 (Q1)	0.27 / 0.34	0.45	-24.44% (-0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ELAN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2026	$22.99	$26.18	+13.88%
Feb 24, 2026	$24.75	$26.38	+6.59%
Nov 05, 2025	$22.50	$21.60	-4.00%
Aug 07, 2025	$13.95	$16.48	+18.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.